Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the 12 best buy-the-dip stocks to invest in now.
On June 10, an underwritten public offering of common stock valued at $500 million was initiated by Summit Therapeutics Inc. (NASDAQ:SMMT)
The company stated in its announcement that 100% of the shares in this proposed transaction are being offered directly by Summit. To manage and coordinate the equity issuance process, the firm has appointed J.P. Morgan, Goldman Sachs & Co., and Citigroup to serve as the joint book-running managers.
Tonhom1009/ On June 1, following the presentation of Phase 3 HARMONi-6 trial data at an ASCO plenary session, Cantor Fitzgerald reaffirmed its Overweight rating on Summit Therapeutics Inc. (NASDAQ:SMMT). As a first-line treatment for squamous non-small cell lung cancer (NSCLC), the China-based research evaluated the combination of ivonescimab and chemotherapy versus tislelizumab plus chemotherapy. The ivonescimab combination produced a median progression-free survival (PFS) of 11 months and a hazard ratio of 0.60, according to previously published results at ESMO 2025.